Review



spearman rank order correlation test graphpad prism v9.0.1  (GraphPad Software Inc)


Bioz Verified Symbol GraphPad Software Inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    GraphPad Software Inc spearman rank order correlation test graphpad prism v9.0.1
    <t>Correlation</t> matrix analysis of DEspR+ neutrophils, clinical parameters and plasma biomarkers in ARDS and COVID19-ARDS. (A) Correlation matrix ARDS: <t>Spearman</t> <t>Rank</t> Correlation, n = 19 patients with ARDS diagnosis (Berlin definition) of cell surface DEspR+ expression levels (% or number #) in CD11b+ activated neutrophils (actNs), monocytes (actMs), and lymphocytes (actLs) and corresponding correlation with 1] clinical parameters of severity [ICU-free days at 28-days, defined as (28 - # of ICU-days) with ICU-death = −1, and > 28-days in the ICU = 0; PsO2/FiO2 or S/F ratio, Sequential Organ Failure Assessment (SOFA) scores on day of FCM-analysis (t1-SOFA), SOFA on day of ICU-discharge or ICU-death (t2-SOFA)]; 2] plasma biomarkers reported to be elevated in ARDS by others [interleukin-6 (IL-6), endothelin-1 (ET1), myeloperoxidase (MPO), terminal complex of complement (sC5b9), and mitochondrial/nuclear DNA ratio (mt/nucl DNA), and 3] NETosis parameters: DEspR+ cytoplast levels with high or low granularity (SSC) on flow cytometry. See for specific values: rho, P-values with power > 0.8. (B) ARDS: neutrophil-to-lymphocyte ratio (NLR) between survivors (S) n = 12, (mean ± sd: 10.96 ± 5.4) and non-survivors (non-S) n = 6 (18.03 ± 11.21), Mann Whitney p = 0.33 (n.s). (C) ARDS: number (#) of cell-surface DEspR+CD11b+ neutrophils (Ns) detected in ARDS-survivors: n = 12, (mean ± sd: 0.8035 ± 0.8) vs non-survivors: n = 6 (8.1 ± 6.0); two-tailed Mann Whitney p = 0.0001 (***), effect size Hedges’ g with 4% correction: 2.03). (D) ARDS: Comparison of % of DEspR+CD11b+ neutrophils in ARDS: survivors: n = 13, (10.3 ± 10.0) vs non-survivors: n = 6, (48.2 ± 6.3); two-tailed Mann Whitney p < 0.0001 (****), effect size Hedges’ g with 4% correction: 4.03. (E) ARDS: Kaplan-Meir Survival curve analysis with threshold for DEspR+CD11b+ neutrophil-counts set at 3 K/μL whole blood as determined from . Log rank (Mantel-Cox) <t>test</t> Chi square 20.56, P < 0.0001, Hazard Ratio (Mantel-Haenszel) 90.5, 95% CI of ratio: 12.91 to 634.7. (F) Correlation matrix COVID19-ARDS: n = 11 (severe COVID19 requiring mechanical ventilation). Parameters as defined in , with addition of # of DEspR+CD11b+ NETosing neutrophils (D+actNETosing Ns), and circularity index of neutrophils (< 0.8 indicative of NETosing neutrophil, see ). (G) COVID19-ARDS: comparison of neutrophil-to-lymphocyte ratio (NLR) between survivors: n = 7 (mean ± sd: 10.7 ± 7.7) and non-survivors: n = 4 (55.3 ± 41.4). two-tailed Mann Whitney p = 0.0242 (*), effect size Hedge’s g with 4% correction: 1.73. (H) COVID19-ARDS: comparison of DEspR+CD11b+ neutrophil-counts (K/μL) in whole blood between survivors: n = 7 (mean ± sd: 3.8 ± 2.99) and non-Survivors: n = 4 (13.8 ± 7.9), two-tailed Mann Whitney p = 0.04 (*), effect size Hedge’s g with 4% correction: 1.82. (I) COVID19-ARDS: #DEspR+ NETosing neutrophil-counts (K/μL) whole blood, survivors: n = 7 (mean ± sd: 1.3 ± 1.29) and non-Survivors: n = 4 (10.0 ± 5.7). Two-tailed Mann Whitney p = 0.0121 (*), effect size Hedge’s g with 4% correction: 2.4.
    Spearman Rank Order Correlation Test Graphpad Prism V9.0.1, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/spearman+rank+order+correlation+test+graphpad+prism+v9%2E0%2E1/spearman%E2%80%99s+correlation+coefficient+performed+by+graphpad+prism+8+2/pmc08452107-269-6-11
    Average 90 stars, based on 1 article reviews
    spearman rank order correlation test graphpad prism v9.0.1 - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "Increased Neutrophil-Subset Associated With Severity/Mortality In ARDS And COVID19-ARDS Expresses The Dual Endothelin-1/VEGFsignal-Peptide Receptor (DEspR): An Actionable Therapeutic Target"

    Article Title: Increased Neutrophil-Subset Associated With Severity/Mortality In ARDS And COVID19-ARDS Expresses The Dual Endothelin-1/VEGFsignal-Peptide Receptor (DEspR): An Actionable Therapeutic Target

    Journal: Research Square

    doi: 10.21203/rs.3.rs-846250/v1

    Correlation matrix analysis of DEspR+ neutrophils, clinical parameters and plasma biomarkers in ARDS and COVID19-ARDS. (A) Correlation matrix ARDS: Spearman Rank Correlation, n = 19 patients with ARDS diagnosis (Berlin definition) of cell surface DEspR+ expression levels (% or number #) in CD11b+ activated neutrophils (actNs), monocytes (actMs), and lymphocytes (actLs) and corresponding correlation with 1] clinical parameters of severity [ICU-free days at 28-days, defined as (28 - # of ICU-days) with ICU-death = −1, and > 28-days in the ICU = 0; PsO2/FiO2 or S/F ratio, Sequential Organ Failure Assessment (SOFA) scores on day of FCM-analysis (t1-SOFA), SOFA on day of ICU-discharge or ICU-death (t2-SOFA)]; 2] plasma biomarkers reported to be elevated in ARDS by others [interleukin-6 (IL-6), endothelin-1 (ET1), myeloperoxidase (MPO), terminal complex of complement (sC5b9), and mitochondrial/nuclear DNA ratio (mt/nucl DNA), and 3] NETosis parameters: DEspR+ cytoplast levels with high or low granularity (SSC) on flow cytometry. See for specific values: rho, P-values with power > 0.8. (B) ARDS: neutrophil-to-lymphocyte ratio (NLR) between survivors (S) n = 12, (mean ± sd: 10.96 ± 5.4) and non-survivors (non-S) n = 6 (18.03 ± 11.21), Mann Whitney p = 0.33 (n.s). (C) ARDS: number (#) of cell-surface DEspR+CD11b+ neutrophils (Ns) detected in ARDS-survivors: n = 12, (mean ± sd: 0.8035 ± 0.8) vs non-survivors: n = 6 (8.1 ± 6.0); two-tailed Mann Whitney p = 0.0001 (***), effect size Hedges’ g with 4% correction: 2.03). (D) ARDS: Comparison of % of DEspR+CD11b+ neutrophils in ARDS: survivors: n = 13, (10.3 ± 10.0) vs non-survivors: n = 6, (48.2 ± 6.3); two-tailed Mann Whitney p < 0.0001 (****), effect size Hedges’ g with 4% correction: 4.03. (E) ARDS: Kaplan-Meir Survival curve analysis with threshold for DEspR+CD11b+ neutrophil-counts set at 3 K/μL whole blood as determined from . Log rank (Mantel-Cox) test Chi square 20.56, P < 0.0001, Hazard Ratio (Mantel-Haenszel) 90.5, 95% CI of ratio: 12.91 to 634.7. (F) Correlation matrix COVID19-ARDS: n = 11 (severe COVID19 requiring mechanical ventilation). Parameters as defined in , with addition of # of DEspR+CD11b+ NETosing neutrophils (D+actNETosing Ns), and circularity index of neutrophils (< 0.8 indicative of NETosing neutrophil, see ). (G) COVID19-ARDS: comparison of neutrophil-to-lymphocyte ratio (NLR) between survivors: n = 7 (mean ± sd: 10.7 ± 7.7) and non-survivors: n = 4 (55.3 ± 41.4). two-tailed Mann Whitney p = 0.0242 (*), effect size Hedge’s g with 4% correction: 1.73. (H) COVID19-ARDS: comparison of DEspR+CD11b+ neutrophil-counts (K/μL) in whole blood between survivors: n = 7 (mean ± sd: 3.8 ± 2.99) and non-Survivors: n = 4 (13.8 ± 7.9), two-tailed Mann Whitney p = 0.04 (*), effect size Hedge’s g with 4% correction: 1.82. (I) COVID19-ARDS: #DEspR+ NETosing neutrophil-counts (K/μL) whole blood, survivors: n = 7 (mean ± sd: 1.3 ± 1.29) and non-Survivors: n = 4 (10.0 ± 5.7). Two-tailed Mann Whitney p = 0.0121 (*), effect size Hedge’s g with 4% correction: 2.4.
    Figure Legend Snippet: Correlation matrix analysis of DEspR+ neutrophils, clinical parameters and plasma biomarkers in ARDS and COVID19-ARDS. (A) Correlation matrix ARDS: Spearman Rank Correlation, n = 19 patients with ARDS diagnosis (Berlin definition) of cell surface DEspR+ expression levels (% or number #) in CD11b+ activated neutrophils (actNs), monocytes (actMs), and lymphocytes (actLs) and corresponding correlation with 1] clinical parameters of severity [ICU-free days at 28-days, defined as (28 - # of ICU-days) with ICU-death = −1, and > 28-days in the ICU = 0; PsO2/FiO2 or S/F ratio, Sequential Organ Failure Assessment (SOFA) scores on day of FCM-analysis (t1-SOFA), SOFA on day of ICU-discharge or ICU-death (t2-SOFA)]; 2] plasma biomarkers reported to be elevated in ARDS by others [interleukin-6 (IL-6), endothelin-1 (ET1), myeloperoxidase (MPO), terminal complex of complement (sC5b9), and mitochondrial/nuclear DNA ratio (mt/nucl DNA), and 3] NETosis parameters: DEspR+ cytoplast levels with high or low granularity (SSC) on flow cytometry. See for specific values: rho, P-values with power > 0.8. (B) ARDS: neutrophil-to-lymphocyte ratio (NLR) between survivors (S) n = 12, (mean ± sd: 10.96 ± 5.4) and non-survivors (non-S) n = 6 (18.03 ± 11.21), Mann Whitney p = 0.33 (n.s). (C) ARDS: number (#) of cell-surface DEspR+CD11b+ neutrophils (Ns) detected in ARDS-survivors: n = 12, (mean ± sd: 0.8035 ± 0.8) vs non-survivors: n = 6 (8.1 ± 6.0); two-tailed Mann Whitney p = 0.0001 (***), effect size Hedges’ g with 4% correction: 2.03). (D) ARDS: Comparison of % of DEspR+CD11b+ neutrophils in ARDS: survivors: n = 13, (10.3 ± 10.0) vs non-survivors: n = 6, (48.2 ± 6.3); two-tailed Mann Whitney p < 0.0001 (****), effect size Hedges’ g with 4% correction: 4.03. (E) ARDS: Kaplan-Meir Survival curve analysis with threshold for DEspR+CD11b+ neutrophil-counts set at 3 K/μL whole blood as determined from . Log rank (Mantel-Cox) test Chi square 20.56, P < 0.0001, Hazard Ratio (Mantel-Haenszel) 90.5, 95% CI of ratio: 12.91 to 634.7. (F) Correlation matrix COVID19-ARDS: n = 11 (severe COVID19 requiring mechanical ventilation). Parameters as defined in , with addition of # of DEspR+CD11b+ NETosing neutrophils (D+actNETosing Ns), and circularity index of neutrophils (< 0.8 indicative of NETosing neutrophil, see ). (G) COVID19-ARDS: comparison of neutrophil-to-lymphocyte ratio (NLR) between survivors: n = 7 (mean ± sd: 10.7 ± 7.7) and non-survivors: n = 4 (55.3 ± 41.4). two-tailed Mann Whitney p = 0.0242 (*), effect size Hedge’s g with 4% correction: 1.73. (H) COVID19-ARDS: comparison of DEspR+CD11b+ neutrophil-counts (K/μL) in whole blood between survivors: n = 7 (mean ± sd: 3.8 ± 2.99) and non-Survivors: n = 4 (13.8 ± 7.9), two-tailed Mann Whitney p = 0.04 (*), effect size Hedge’s g with 4% correction: 1.82. (I) COVID19-ARDS: #DEspR+ NETosing neutrophil-counts (K/μL) whole blood, survivors: n = 7 (mean ± sd: 1.3 ± 1.29) and non-Survivors: n = 4 (10.0 ± 5.7). Two-tailed Mann Whitney p = 0.0121 (*), effect size Hedge’s g with 4% correction: 2.4.

    Techniques Used: Clinical Proteomics, Biomarker Discovery, Expressing, Flow Cytometry, MANN-WHITNEY, Two Tailed Test, Comparison

     Spearman Rank Correlation  matrix analysis: COVID19-ARDS subjects requiring ventilator support.
    Figure Legend Snippet: Spearman Rank Correlation matrix analysis: COVID19-ARDS subjects requiring ventilator support.

    Techniques Used: Flow Cytometry, Immunofluorescence

    ( A ) Representative epifluorescence/DIC images of IF-stained blood smears from ARDS-non-survivor* ARDS-survivor, and non-ARDS critically ill patient in the ICU, DEspR+ NETosing neutrophils (dashed ○) and cytoplasts (➔). anuclear (DAPI−) red blood cells (RBCs) relief images in background. Bar = 20 μm. ( B ) Representative epifluorescence/DIC images of IF-stained blood smears from COVID19-ARDS non-survivor and survivor. IF-staining identical to panel A: inset: DEspR+ NETosing neutrophils prior to merged DAPI+DEspR+ image of NETosing neutrophils with extruded DNA-interconnections among neutrophils. Middle panel: triple-merged DEspR+CD11b+DAPI+ NETosing neutrophils with extruded DNA-interconnections. ( C ) Representative COVIDl9-ARDS-survivor showing minimal NETosing neutrophils. ( D-E ) Representative image of filamentous DEspR-bound extruded DNA networks in IF-stained blood smears from ARDS-patient ( D ) and COVID19-ARDS patient ( E ). ( F ) Analysis of circularity to distinguish NETosing neutrophil with low circularity from non-NETosing neutrophils with circularity index approaching 1.0. ( G ) Spearman rank correlation analysis of # DEspR+CD11b+ neutrophils and mean circularity index (average from n > 500 neutrophils per patient) in COVID19-ARDS patients (n = 11): negative correlation (r s = −0.782, P = 0.0064). ( H ) Flow cytometry analysis of FSC SSC and CD11b+ gated cytoplasts comparing levels in ARDS survivor (3.8%) vs ARDS non-survivor (29.77 %).
    Figure Legend Snippet: ( A ) Representative epifluorescence/DIC images of IF-stained blood smears from ARDS-non-survivor* ARDS-survivor, and non-ARDS critically ill patient in the ICU, DEspR+ NETosing neutrophils (dashed ○) and cytoplasts (➔). anuclear (DAPI−) red blood cells (RBCs) relief images in background. Bar = 20 μm. ( B ) Representative epifluorescence/DIC images of IF-stained blood smears from COVID19-ARDS non-survivor and survivor. IF-staining identical to panel A: inset: DEspR+ NETosing neutrophils prior to merged DAPI+DEspR+ image of NETosing neutrophils with extruded DNA-interconnections among neutrophils. Middle panel: triple-merged DEspR+CD11b+DAPI+ NETosing neutrophils with extruded DNA-interconnections. ( C ) Representative COVIDl9-ARDS-survivor showing minimal NETosing neutrophils. ( D-E ) Representative image of filamentous DEspR-bound extruded DNA networks in IF-stained blood smears from ARDS-patient ( D ) and COVID19-ARDS patient ( E ). ( F ) Analysis of circularity to distinguish NETosing neutrophil with low circularity from non-NETosing neutrophils with circularity index approaching 1.0. ( G ) Spearman rank correlation analysis of # DEspR+CD11b+ neutrophils and mean circularity index (average from n > 500 neutrophils per patient) in COVID19-ARDS patients (n = 11): negative correlation (r s = −0.782, P = 0.0064). ( H ) Flow cytometry analysis of FSC SSC and CD11b+ gated cytoplasts comparing levels in ARDS survivor (3.8%) vs ARDS non-survivor (29.77 %).

    Techniques Used: Staining, Flow Cytometry

    Related Articles

    Software:

    Article Title: Increased Neutrophil-Subset Associated With Severity/Mortality In ARDS And COVID19-ARDS Expresses The Dual Endothelin-1/VEGFsignal-Peptide Receptor (DEspR): An Actionable Therapeutic Target
    Article Snippet: For survivor vs non-survivor group comparisons, we used the two-tailed Mann Whitney test (GraphPad Prism v9.0.1) with effect size calculated via Hedge’s g with 4% correction. .. Correlations were calculated by using the Spearman Rank Order correlation test (GraphPad Prism v9.0.1) and power calculations determined by using SigmaPlot 11.0 software. ..



    Similar Products

    90
    GraphPad Software Inc spearman rank order correlation test graphpad prism v9.0.1
    <t>Correlation</t> matrix analysis of DEspR+ neutrophils, clinical parameters and plasma biomarkers in ARDS and COVID19-ARDS. (A) Correlation matrix ARDS: <t>Spearman</t> <t>Rank</t> Correlation, n = 19 patients with ARDS diagnosis (Berlin definition) of cell surface DEspR+ expression levels (% or number #) in CD11b+ activated neutrophils (actNs), monocytes (actMs), and lymphocytes (actLs) and corresponding correlation with 1] clinical parameters of severity [ICU-free days at 28-days, defined as (28 - # of ICU-days) with ICU-death = −1, and > 28-days in the ICU = 0; PsO2/FiO2 or S/F ratio, Sequential Organ Failure Assessment (SOFA) scores on day of FCM-analysis (t1-SOFA), SOFA on day of ICU-discharge or ICU-death (t2-SOFA)]; 2] plasma biomarkers reported to be elevated in ARDS by others [interleukin-6 (IL-6), endothelin-1 (ET1), myeloperoxidase (MPO), terminal complex of complement (sC5b9), and mitochondrial/nuclear DNA ratio (mt/nucl DNA), and 3] NETosis parameters: DEspR+ cytoplast levels with high or low granularity (SSC) on flow cytometry. See for specific values: rho, P-values with power > 0.8. (B) ARDS: neutrophil-to-lymphocyte ratio (NLR) between survivors (S) n = 12, (mean ± sd: 10.96 ± 5.4) and non-survivors (non-S) n = 6 (18.03 ± 11.21), Mann Whitney p = 0.33 (n.s). (C) ARDS: number (#) of cell-surface DEspR+CD11b+ neutrophils (Ns) detected in ARDS-survivors: n = 12, (mean ± sd: 0.8035 ± 0.8) vs non-survivors: n = 6 (8.1 ± 6.0); two-tailed Mann Whitney p = 0.0001 (***), effect size Hedges’ g with 4% correction: 2.03). (D) ARDS: Comparison of % of DEspR+CD11b+ neutrophils in ARDS: survivors: n = 13, (10.3 ± 10.0) vs non-survivors: n = 6, (48.2 ± 6.3); two-tailed Mann Whitney p < 0.0001 (****), effect size Hedges’ g with 4% correction: 4.03. (E) ARDS: Kaplan-Meir Survival curve analysis with threshold for DEspR+CD11b+ neutrophil-counts set at 3 K/μL whole blood as determined from . Log rank (Mantel-Cox) <t>test</t> Chi square 20.56, P < 0.0001, Hazard Ratio (Mantel-Haenszel) 90.5, 95% CI of ratio: 12.91 to 634.7. (F) Correlation matrix COVID19-ARDS: n = 11 (severe COVID19 requiring mechanical ventilation). Parameters as defined in , with addition of # of DEspR+CD11b+ NETosing neutrophils (D+actNETosing Ns), and circularity index of neutrophils (< 0.8 indicative of NETosing neutrophil, see ). (G) COVID19-ARDS: comparison of neutrophil-to-lymphocyte ratio (NLR) between survivors: n = 7 (mean ± sd: 10.7 ± 7.7) and non-survivors: n = 4 (55.3 ± 41.4). two-tailed Mann Whitney p = 0.0242 (*), effect size Hedge’s g with 4% correction: 1.73. (H) COVID19-ARDS: comparison of DEspR+CD11b+ neutrophil-counts (K/μL) in whole blood between survivors: n = 7 (mean ± sd: 3.8 ± 2.99) and non-Survivors: n = 4 (13.8 ± 7.9), two-tailed Mann Whitney p = 0.04 (*), effect size Hedge’s g with 4% correction: 1.82. (I) COVID19-ARDS: #DEspR+ NETosing neutrophil-counts (K/μL) whole blood, survivors: n = 7 (mean ± sd: 1.3 ± 1.29) and non-Survivors: n = 4 (10.0 ± 5.7). Two-tailed Mann Whitney p = 0.0121 (*), effect size Hedge’s g with 4% correction: 2.4.
    Spearman Rank Order Correlation Test Graphpad Prism V9.0.1, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/spearman+rank+order+correlation+test+graphpad+prism+v9%2E0%2E1/spearman%E2%80%99s+correlation+coefficient+performed+by+graphpad+prism+8+2/pmc08452107-269-6-11
    Average 90 stars, based on 1 article reviews
    spearman rank order correlation test graphpad prism v9.0.1 - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    Image Search Results


    Correlation matrix analysis of DEspR+ neutrophils, clinical parameters and plasma biomarkers in ARDS and COVID19-ARDS. (A) Correlation matrix ARDS: Spearman Rank Correlation, n = 19 patients with ARDS diagnosis (Berlin definition) of cell surface DEspR+ expression levels (% or number #) in CD11b+ activated neutrophils (actNs), monocytes (actMs), and lymphocytes (actLs) and corresponding correlation with 1] clinical parameters of severity [ICU-free days at 28-days, defined as (28 - # of ICU-days) with ICU-death = −1, and > 28-days in the ICU = 0; PsO2/FiO2 or S/F ratio, Sequential Organ Failure Assessment (SOFA) scores on day of FCM-analysis (t1-SOFA), SOFA on day of ICU-discharge or ICU-death (t2-SOFA)]; 2] plasma biomarkers reported to be elevated in ARDS by others [interleukin-6 (IL-6), endothelin-1 (ET1), myeloperoxidase (MPO), terminal complex of complement (sC5b9), and mitochondrial/nuclear DNA ratio (mt/nucl DNA), and 3] NETosis parameters: DEspR+ cytoplast levels with high or low granularity (SSC) on flow cytometry. See for specific values: rho, P-values with power > 0.8. (B) ARDS: neutrophil-to-lymphocyte ratio (NLR) between survivors (S) n = 12, (mean ± sd: 10.96 ± 5.4) and non-survivors (non-S) n = 6 (18.03 ± 11.21), Mann Whitney p = 0.33 (n.s). (C) ARDS: number (#) of cell-surface DEspR+CD11b+ neutrophils (Ns) detected in ARDS-survivors: n = 12, (mean ± sd: 0.8035 ± 0.8) vs non-survivors: n = 6 (8.1 ± 6.0); two-tailed Mann Whitney p = 0.0001 (***), effect size Hedges’ g with 4% correction: 2.03). (D) ARDS: Comparison of % of DEspR+CD11b+ neutrophils in ARDS: survivors: n = 13, (10.3 ± 10.0) vs non-survivors: n = 6, (48.2 ± 6.3); two-tailed Mann Whitney p < 0.0001 (****), effect size Hedges’ g with 4% correction: 4.03. (E) ARDS: Kaplan-Meir Survival curve analysis with threshold for DEspR+CD11b+ neutrophil-counts set at 3 K/μL whole blood as determined from . Log rank (Mantel-Cox) test Chi square 20.56, P < 0.0001, Hazard Ratio (Mantel-Haenszel) 90.5, 95% CI of ratio: 12.91 to 634.7. (F) Correlation matrix COVID19-ARDS: n = 11 (severe COVID19 requiring mechanical ventilation). Parameters as defined in , with addition of # of DEspR+CD11b+ NETosing neutrophils (D+actNETosing Ns), and circularity index of neutrophils (< 0.8 indicative of NETosing neutrophil, see ). (G) COVID19-ARDS: comparison of neutrophil-to-lymphocyte ratio (NLR) between survivors: n = 7 (mean ± sd: 10.7 ± 7.7) and non-survivors: n = 4 (55.3 ± 41.4). two-tailed Mann Whitney p = 0.0242 (*), effect size Hedge’s g with 4% correction: 1.73. (H) COVID19-ARDS: comparison of DEspR+CD11b+ neutrophil-counts (K/μL) in whole blood between survivors: n = 7 (mean ± sd: 3.8 ± 2.99) and non-Survivors: n = 4 (13.8 ± 7.9), two-tailed Mann Whitney p = 0.04 (*), effect size Hedge’s g with 4% correction: 1.82. (I) COVID19-ARDS: #DEspR+ NETosing neutrophil-counts (K/μL) whole blood, survivors: n = 7 (mean ± sd: 1.3 ± 1.29) and non-Survivors: n = 4 (10.0 ± 5.7). Two-tailed Mann Whitney p = 0.0121 (*), effect size Hedge’s g with 4% correction: 2.4.

    Journal: Research Square

    Article Title: Increased Neutrophil-Subset Associated With Severity/Mortality In ARDS And COVID19-ARDS Expresses The Dual Endothelin-1/VEGFsignal-Peptide Receptor (DEspR): An Actionable Therapeutic Target

    doi: 10.21203/rs.3.rs-846250/v1

    Figure Lengend Snippet: Correlation matrix analysis of DEspR+ neutrophils, clinical parameters and plasma biomarkers in ARDS and COVID19-ARDS. (A) Correlation matrix ARDS: Spearman Rank Correlation, n = 19 patients with ARDS diagnosis (Berlin definition) of cell surface DEspR+ expression levels (% or number #) in CD11b+ activated neutrophils (actNs), monocytes (actMs), and lymphocytes (actLs) and corresponding correlation with 1] clinical parameters of severity [ICU-free days at 28-days, defined as (28 - # of ICU-days) with ICU-death = −1, and > 28-days in the ICU = 0; PsO2/FiO2 or S/F ratio, Sequential Organ Failure Assessment (SOFA) scores on day of FCM-analysis (t1-SOFA), SOFA on day of ICU-discharge or ICU-death (t2-SOFA)]; 2] plasma biomarkers reported to be elevated in ARDS by others [interleukin-6 (IL-6), endothelin-1 (ET1), myeloperoxidase (MPO), terminal complex of complement (sC5b9), and mitochondrial/nuclear DNA ratio (mt/nucl DNA), and 3] NETosis parameters: DEspR+ cytoplast levels with high or low granularity (SSC) on flow cytometry. See for specific values: rho, P-values with power > 0.8. (B) ARDS: neutrophil-to-lymphocyte ratio (NLR) between survivors (S) n = 12, (mean ± sd: 10.96 ± 5.4) and non-survivors (non-S) n = 6 (18.03 ± 11.21), Mann Whitney p = 0.33 (n.s). (C) ARDS: number (#) of cell-surface DEspR+CD11b+ neutrophils (Ns) detected in ARDS-survivors: n = 12, (mean ± sd: 0.8035 ± 0.8) vs non-survivors: n = 6 (8.1 ± 6.0); two-tailed Mann Whitney p = 0.0001 (***), effect size Hedges’ g with 4% correction: 2.03). (D) ARDS: Comparison of % of DEspR+CD11b+ neutrophils in ARDS: survivors: n = 13, (10.3 ± 10.0) vs non-survivors: n = 6, (48.2 ± 6.3); two-tailed Mann Whitney p < 0.0001 (****), effect size Hedges’ g with 4% correction: 4.03. (E) ARDS: Kaplan-Meir Survival curve analysis with threshold for DEspR+CD11b+ neutrophil-counts set at 3 K/μL whole blood as determined from . Log rank (Mantel-Cox) test Chi square 20.56, P < 0.0001, Hazard Ratio (Mantel-Haenszel) 90.5, 95% CI of ratio: 12.91 to 634.7. (F) Correlation matrix COVID19-ARDS: n = 11 (severe COVID19 requiring mechanical ventilation). Parameters as defined in , with addition of # of DEspR+CD11b+ NETosing neutrophils (D+actNETosing Ns), and circularity index of neutrophils (< 0.8 indicative of NETosing neutrophil, see ). (G) COVID19-ARDS: comparison of neutrophil-to-lymphocyte ratio (NLR) between survivors: n = 7 (mean ± sd: 10.7 ± 7.7) and non-survivors: n = 4 (55.3 ± 41.4). two-tailed Mann Whitney p = 0.0242 (*), effect size Hedge’s g with 4% correction: 1.73. (H) COVID19-ARDS: comparison of DEspR+CD11b+ neutrophil-counts (K/μL) in whole blood between survivors: n = 7 (mean ± sd: 3.8 ± 2.99) and non-Survivors: n = 4 (13.8 ± 7.9), two-tailed Mann Whitney p = 0.04 (*), effect size Hedge’s g with 4% correction: 1.82. (I) COVID19-ARDS: #DEspR+ NETosing neutrophil-counts (K/μL) whole blood, survivors: n = 7 (mean ± sd: 1.3 ± 1.29) and non-Survivors: n = 4 (10.0 ± 5.7). Two-tailed Mann Whitney p = 0.0121 (*), effect size Hedge’s g with 4% correction: 2.4.

    Article Snippet: Correlations were calculated by using the Spearman Rank Order correlation test (GraphPad Prism v9.0.1) and power calculations determined by using SigmaPlot 11.0 software.

    Techniques: Clinical Proteomics, Biomarker Discovery, Expressing, Flow Cytometry, MANN-WHITNEY, Two Tailed Test, Comparison

     Spearman Rank Correlation  matrix analysis: COVID19-ARDS subjects requiring ventilator support.

    Journal: Research Square

    Article Title: Increased Neutrophil-Subset Associated With Severity/Mortality In ARDS And COVID19-ARDS Expresses The Dual Endothelin-1/VEGFsignal-Peptide Receptor (DEspR): An Actionable Therapeutic Target

    doi: 10.21203/rs.3.rs-846250/v1

    Figure Lengend Snippet: Spearman Rank Correlation matrix analysis: COVID19-ARDS subjects requiring ventilator support.

    Article Snippet: Correlations were calculated by using the Spearman Rank Order correlation test (GraphPad Prism v9.0.1) and power calculations determined by using SigmaPlot 11.0 software.

    Techniques: Flow Cytometry, Immunofluorescence

    ( A ) Representative epifluorescence/DIC images of IF-stained blood smears from ARDS-non-survivor* ARDS-survivor, and non-ARDS critically ill patient in the ICU, DEspR+ NETosing neutrophils (dashed ○) and cytoplasts (➔). anuclear (DAPI−) red blood cells (RBCs) relief images in background. Bar = 20 μm. ( B ) Representative epifluorescence/DIC images of IF-stained blood smears from COVID19-ARDS non-survivor and survivor. IF-staining identical to panel A: inset: DEspR+ NETosing neutrophils prior to merged DAPI+DEspR+ image of NETosing neutrophils with extruded DNA-interconnections among neutrophils. Middle panel: triple-merged DEspR+CD11b+DAPI+ NETosing neutrophils with extruded DNA-interconnections. ( C ) Representative COVIDl9-ARDS-survivor showing minimal NETosing neutrophils. ( D-E ) Representative image of filamentous DEspR-bound extruded DNA networks in IF-stained blood smears from ARDS-patient ( D ) and COVID19-ARDS patient ( E ). ( F ) Analysis of circularity to distinguish NETosing neutrophil with low circularity from non-NETosing neutrophils with circularity index approaching 1.0. ( G ) Spearman rank correlation analysis of # DEspR+CD11b+ neutrophils and mean circularity index (average from n > 500 neutrophils per patient) in COVID19-ARDS patients (n = 11): negative correlation (r s = −0.782, P = 0.0064). ( H ) Flow cytometry analysis of FSC SSC and CD11b+ gated cytoplasts comparing levels in ARDS survivor (3.8%) vs ARDS non-survivor (29.77 %).

    Journal: Research Square

    Article Title: Increased Neutrophil-Subset Associated With Severity/Mortality In ARDS And COVID19-ARDS Expresses The Dual Endothelin-1/VEGFsignal-Peptide Receptor (DEspR): An Actionable Therapeutic Target

    doi: 10.21203/rs.3.rs-846250/v1

    Figure Lengend Snippet: ( A ) Representative epifluorescence/DIC images of IF-stained blood smears from ARDS-non-survivor* ARDS-survivor, and non-ARDS critically ill patient in the ICU, DEspR+ NETosing neutrophils (dashed ○) and cytoplasts (➔). anuclear (DAPI−) red blood cells (RBCs) relief images in background. Bar = 20 μm. ( B ) Representative epifluorescence/DIC images of IF-stained blood smears from COVID19-ARDS non-survivor and survivor. IF-staining identical to panel A: inset: DEspR+ NETosing neutrophils prior to merged DAPI+DEspR+ image of NETosing neutrophils with extruded DNA-interconnections among neutrophils. Middle panel: triple-merged DEspR+CD11b+DAPI+ NETosing neutrophils with extruded DNA-interconnections. ( C ) Representative COVIDl9-ARDS-survivor showing minimal NETosing neutrophils. ( D-E ) Representative image of filamentous DEspR-bound extruded DNA networks in IF-stained blood smears from ARDS-patient ( D ) and COVID19-ARDS patient ( E ). ( F ) Analysis of circularity to distinguish NETosing neutrophil with low circularity from non-NETosing neutrophils with circularity index approaching 1.0. ( G ) Spearman rank correlation analysis of # DEspR+CD11b+ neutrophils and mean circularity index (average from n > 500 neutrophils per patient) in COVID19-ARDS patients (n = 11): negative correlation (r s = −0.782, P = 0.0064). ( H ) Flow cytometry analysis of FSC SSC and CD11b+ gated cytoplasts comparing levels in ARDS survivor (3.8%) vs ARDS non-survivor (29.77 %).

    Article Snippet: Correlations were calculated by using the Spearman Rank Order correlation test (GraphPad Prism v9.0.1) and power calculations determined by using SigmaPlot 11.0 software.

    Techniques: Staining, Flow Cytometry